Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
| Title: | Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol |
|---|---|
| Authors: | Schwartz, GG; Szarek, M; Bittner, VA; Diaz, R; Goodman, SG; Jukema, JW; Landmesser, U; López-Jaramillo, P; Manvelian, G; Pordy, R; Scemama, M; Sinnaeve, PR; White, HD; Steg, PG; Bhatt, DL; Harrington, RA; Zeiher, AM; Tricoci, P; Roe, MT; Mahaffey, KW; Edelberg, JM; Hanotin, C; Lecorps, G; Moryusef, A; Sasiela, WJ; Tamby, JF; Aylward, PE; Drexel, H; Dilic, M; Lopes, RD; Gotcheva, NN; Prieto, JC; Yong, H; Pećin, I; Reiner, Z; Ostadal, P; Poulsen, SH; Viigimaa, M; Nieminen, MS; Danchin, N; Chumburidze, V; Marx, N; Liberopoulos, E; Montenegro Valdovinos, PC; Tse, HF; Kiss, RG; Xavier, D; Zahger, D; Valgimigli, M; Kimura, T; Kim, HS; Kim, SH; Erglis, A; Laucevicius, A; Kedev, S; Yusoff, K; Ramos López, GA; Alings, M; Halvorsen, S; Correa Flores, RM; Sy, RG; Budaj, A; Morais, J; Dorobantu, M; Karpov, Y; Ristic, AD; Chua, T; Murin, J; Fras, Z; Dalby, AJ; Tuñón, J; Asita de Silva, H; Hagström, E; Müller, C; Chiang, CE; Sritara, P; Guneri, S; Parkhomenko, A; Ray, KK; Moriarty, PM; Vogel, R; Chaitman, B; Kelsey, SF; Olsson, AG; Rouleau, JL; Simoons, ML; Alexander, K; Meloni, C; Rosenson, R; Sijbrands, EJG; Alexander, JH; Armaganijan, L; Bagai, A; Bahit, MC; Brennan, JM; Clifton, S; DeVore, AD; Deloatch, S; Dickey, S; Dombrowski, K |
| Publisher Information: | Elsevier BV |
| Publication Year: | 2021 |
| Collection: | The University of Liverpool Repository |
| Description: | Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. Objectives: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels. Methods: ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was 13.7 mg/dL or ≤13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% CI: 0.72-0.92) and 0.89 (95% CI: 0.75-1.06), with P interaction = 0.43. Conclusions: In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein ... |
| Document Type: | article in journal/newspaper |
| File Description: | application/pdf |
| Language: | English |
| ISSN: | 0735-1097 |
| Relation: | https://livrepository.liverpool.ac.uk/3173689/1/Lipoprotein%28a%29%20and%20Benefit%20of%20PCSK9%20Inhibition%20in%20Patients%20With%20Nominally%20Controlled%20LDL%20Cholesterol.pdf; Collapse authors list. Schwartz, GG, Szarek, M, Bittner, VA, Diaz, R, Goodman, SG, Jukema, JW, Landmesser, U, López-Jaramillo, P, Manvelian, G, Pordy, R et al (show 90 more authors) , Scemama, M, Sinnaeve, PR, White, HD, Steg, PG, Bhatt, DL, Harrington, RA, Zeiher, AM, Tricoci, P, Roe, MT, Mahaffey, KW, Edelberg, JM, Hanotin, C, Lecorps, G, Moryusef, A, Sasiela, WJ, Tamby, JF, Aylward, PE, Drexel, H, Dilic, M, Lopes, RD, Gotcheva, NN, Prieto, JC, Yong, H, Pećin, I, Reiner, Z, Ostadal, P, Poulsen, SH, Viigimaa, M, Nieminen, MS, Danchin, N, Chumburidze, V, Marx, N, Liberopoulos, E, Montenegro Valdovinos, PC, Tse, HF, Kiss, RG, Xavier, D, Zahger, D, Valgimigli, M, Kimura, T, Kim, HS, Kim, SH, Erglis, A, Laucevicius, A, Kedev, S, Yusoff, K, Ramos López, GA, Alings, M, Halvorsen, S, Correa Flores, RM, Sy, RG, Budaj, A, Morais, J, Dorobantu, M, Karpov, Y, Ristic, AD, Chua, T, Murin, J, Fras, Z, Dalby, AJ, Tuñón, J, Asita de Silva, H, Hagström, E, Müller, C, Chiang, CE, Sritara, P, Guneri, S, Parkhomenko, A, Ray, KK, Moriarty, PM, Vogel, R, Chaitman, B, Kelsey, SF, Olsson, AG, Rouleau, JL, Simoons, ML, Alexander, K, Meloni, C, Rosenson, R, Sijbrands, EJG, Alexander, JH, Armaganijan, L, Bagai, A, Bahit, MC, Brennan, JM, Clifton, S, DeVore, AD, Deloatch, S, Dickey, S and Dombrowski, K (2021) Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol Journal of the American College of Cardiology, 78 (5). pp. 421-433. ISSN 0735-1097, 1558-3597 |
| DOI: | 10.1016/j.jacc.2021.04.102 |
| Availability: | https://livrepository.liverpool.ac.uk/3173689/; https://doi.org/10.1016/j.jacc.2021.04.102; https://livrepository.liverpool.ac.uk/3173689/1/Lipoprotein%28a%29%20and%20Benefit%20of%20PCSK9%20Inhibition%20in%20Patients%20With%20Nominally%20Controlled%20LDL%20Cholesterol.pdf |
| Accession Number: | edsbas.83F95E3E |
| Database: | BASE |